Scholars Central

Conference abstractPublished 26 Sep 2017

The effect of lopinavir/ritonavir and lopinavir/ritonavir loaded PLGA nanoparticles on experimental toxoplasmosis

Authors: Iman Abou-El-Naga, Eman Elkerdany, Rasha Mady, Thanaa Shalaby, Inas Zaytoun

University of Alexandria, Egypt

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

After the introduction of HIV protease inhibitors (HIV-PIs), a marked reduction has been achieved in the incidence and clinical course of toxoplasmic encephalitis. The current work was undertaken to study for the first time, the efficacy of HIV-PIs against Toxoplasma gondii infection in acute experimental toxoplasmosis. Lopinavir/Ritonavir (L/R) was used in the same ration present in alluvia, a known HIV-PIs drug used in the developing countries in the regimens of AIDâÂ?Â?s patient treatment. Poly lactic-co-glycolic acid (PLGA) nanoparticles were used as a delivery system to L/R therapy. Both forms caused parasitological improvement. The higher efficacy was achieved by using L/R PLGA together with decrease in the effective dose. There was reduction in the parasite count in the peritoneum and the liver, parasite viability and infectivity. The antitoxoplasma effect of the drug was attributed to the morphological distortion of the tachyzoites as evident by the ultrastructure examination. Moreover, the treatment affected the egress of tachyzoites which remained enclosed within a membranous structure thus delayed the infection of new host cells. L/R also induced apoptosis and autophagy in extracellular and intracellular Toxoplasma gondii tachyzoites. The parasitophorous vacuole membrane was disrupted and vesiculated. The nanotubular networks inside the parasitophorous vacuole that are involved in nutrient acquisition were disrupted. Therefore, the present work opens a new possible way for the approved HIV-PIs as an alternative treatment against acute toxoplasmosis. Furthermore, it increases the list of the opportunistic parasites that can be treated by this drug. The successful in vivo effect of HIV-PIs against Toxoplasma gondii suggests that this parasite could be a target in HIV treated patients, thus decreases the possibility of toxoplasmic encephalitis development.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Infectious Diseases & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Infectious Diseases & Therapy
  • SubjectInfectious Diseases
  • BylineArticles whose byline prints “Iman Abou-El-Naga”
  • BylineArticles whose byline prints “Eman Elkerdany”
  • BylineArticles whose byline prints “Rasha Mady”
  • BylineArticles whose byline prints “Thanaa Shalaby”
  • BylineArticles whose byline prints “Inas Zaytoun”